- Home
- VLY vs IKT Comparison
VLY vs IKT Comparison
Compare VLY & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VLY
- IKT
- Stock Information
- Founded
- VLY 1927
- IKT 2008
- Country
- VLY United States
- IKT United States
- Employees
- VLY N/A
- IKT N/A
- Industry
- VLY Major Banks
- IKT Biotechnology: Pharmaceutical Preparations
- Sector
- VLY Finance
- IKT Health Care
- Exchange
- VLY Nasdaq
- IKT Nasdaq
- Market Cap
- VLY 5.2B
- IKT 140.5M
- IPO Year
- VLY N/A
- IKT 2020
- Fundamental
- Price
- VLY $11.06
- IKT $1.60
- Analyst Decision
- VLY Buy
- IKT Buy
- Analyst Count
- VLY 12
- IKT 2
- Target Price
- VLY $11.75
- IKT $8.00
- AVG Volume (30 Days)
- VLY 7.6M
- IKT 92.1K
- Earning Date
- VLY 10-23-2025
- IKT 11-13-2025
- Dividend Yield
- VLY 4.10%
- IKT N/A
- EPS Growth
- VLY 9.10
- IKT N/A
- EPS
- VLY 0.78
- IKT N/A
- Revenue
- VLY $1,603,358,000.00
- IKT N/A
- Revenue This Year
- VLY $33.98
- IKT N/A
- Revenue Next Year
- VLY $8.90
- IKT N/A
- P/E Ratio
- VLY $13.77
- IKT N/A
- Revenue Growth
- VLY N/A
- IKT N/A
- 52 Week Low
- VLY $7.48
- IKT $1.12
- 52 Week High
- VLY $11.10
- IKT $4.20
- Technical
- Relative Strength Index (RSI)
- VLY 72.77
- IKT 44.59
- Support Level
- VLY $10.46
- IKT $1.50
- Resistance Level
- VLY $10.94
- IKT $1.63
- Average True Range (ATR)
- VLY 0.25
- IKT 0.09
- MACD
- VLY -0.01
- IKT -0.01
- Stochastic Oscillator
- VLY 96.46
- IKT 26.55
About VLY Valley National Bancorp
Valley National Bancorp is a bank holding company that offers a full suite of national and regional banking solutions through various commercial, private banking, retail, insurance, and wealth management financial services products. It provides personalized service and customized solutions to assist its customers with their financial service needs. The group also offers niche financial services, including loan and deposit products for homeowners associations, cannabis-related business banking, and venture banking, which offers nationally. It manages its business operations under operating segments consisting of Consumer Banking; Commercial Banking; and Treasury and Corporate Other. The group generates the majority of its revenue from the Commercial Banking Segment.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.